Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2026-01-30 Director's Dealing
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of an executive (Kim Jeong-jun) at Qurient Co., Ltd. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2026-01-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by executives and major shareholders to report changes in their shareholdings, commonly known as 'Director's Dealing' or 'Insider Trading' reports. Based on the provided categories, this fits the 'Director's Dealing' (DIRS) classification.
2026-01-30 Korean
기타시장안내 (연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice from a company (Qurient) regarding its compliance with specific KOSDAQ market listing rules (revenue exemption for R&D companies). It does not constitute a full financial report, proxy, or earnings release, but rather a formal regulatory disclosure/announcement. Given it does not fit into specific categories like M&A, dividends, or share buybacks, it falls under the general regulatory filing category.
2026-01-05 Korean
전환청구권행사 (제1회차)
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (CB) into common shares. This involves a change in the company's capital structure as debt is converted into equity. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2025-12-30 Korean
투자판단관련주요경영사항(임상시험결과) (항암치료제 아드릭세티닙(Q702)의 미국 FDA 임상 1상 임상시험 결과보고서(CSR) 수령)
Legal Proceedings Report Classification · 95% confidence The document is a formal regulatory disclosure filed by a company (Curient) regarding the results of a Phase 1 clinical trial for its drug candidate, Q702. It details the trial methodology, safety profile, and outcomes (RP2D determination). In the context of financial filings, disclosures regarding clinical trial results, regulatory approvals, or significant business developments that do not fit into specific categories like 'Annual Report' or 'Earnings Release' are classified as 'Regulatory Filings' (RNS) in this taxonomy, as they serve as official corporate announcements to the exchange.
2025-12-29 Korean
[기재정정]타법인주식및출자증권취득결정 (독일 자회사 QLi5 Therapeutics AG 출자 결정)
Capital/Financing Update Classification · 98% confidence The document is a regulatory filing from the Korean DART system regarding the 'Acquisition of Shares and Securities of Other Corporations' (타법인주식및출자증권취득결정). It details a capital injection into a subsidiary (QLi5 Therapeutics AG) and is a formal disclosure of a corporate transaction. Since it does not fit into specific categories like M&A (which usually implies a change in control or business combination) or Share Issue (which is for the company's own shares), it falls under the general regulatory filing category.
2025-12-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.